MD Anderson, Xencor partner on XmAb candidates

By The Science Advisory Board staff writers

September 4, 2020 -- The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together, they will collaborate to design and execute clinical studies with Xencor's X monoclonal antibody (XmAb) drug candidates.

The drug candidates include novel bispecific antibodies and engineered cytokines with a heterodimer Fc domain, which enables rapid design, simplified development, and stable structure. Nine XmAb bispecific antibodies and one engineered cytokine are being evaluated in phase I clinical studies conducted by Xencor and its partners:

  • CD3 bispecific antibodies (CD123 x CD3, CD20 x CD3, SSTR2 x CD3) that contain a tumor associated antigen and a second binding domain targeted to CD3, an activating receptor on T cells
  • Tumor microenvironment activator bispecific antibodies incorporating Xencor's Xtend technology for increased half-life (XmAb20717, XmAb22841, XmAb23104)
  • Cytokines built with Xencor's XmAb bispecific Fc domain for improved potency and Xtend technology for increased half-life (XmAb24306, co-developed with Genetech)

Xencor has committed to funding and supporting these studies over an initial five-year term.

Xencor, Atreca to work on T cell-based cancer therapies
Biopharmaceutical company Xencor and biotechnology company Atreca have entered into a license agreement to research, develop, and commercialize T cell-engaging...
CNS Pharma partners with MD Anderson
Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center...
Xencor, Vir partner on COVID-19 antibodies research
Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments...
Scientists in the Lab: Featuring Rajan Chaudhari
We are thrilled to introduce our next laboratory scientist this month, who works at the intersection of chemistry, drug development, and data science....
Scientists in the Lab: Featuring Lisa Mustachio
Continuing our feature series this January, ScienceBoard is happy to highlight the work of laboratory scientists, including Lisa Maria Mustachio, PhD,...

Copyright © 2020

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter